report cover

Global and United States Spinal Muscular Atrophy Medicine Market Report & Forecast 2022-2028

  • 07 October 2022
  • Life Sciences
  • 111 Pages
  • Report code : 24WT-7417673

Spinal Muscular Atrophy Medicine Market

1 Study Coverage
1.1 Spinal Muscular Atrophy Medicine Product Introduction
1.2 Global Spinal Muscular Atrophy Medicine Outlook 2017 VS 2022 VS 2028
1.2.1 Global Spinal Muscular Atrophy Medicine Sales in US$ Million for the Year 2017-2028
1.2.2 Global Spinal Muscular Atrophy Medicine Sales in Volume for the Year 2017-2028
1.3 United States Spinal Muscular Atrophy Medicine Outlook 2017 VS 2022 VS 2028
1.3.1 United States Spinal Muscular Atrophy Medicine Sales in US$ Million for the Year 2017-2028
1.3.2 United States Spinal Muscular Atrophy Medicine Sales in Volume for the Year 2017-2028
1.4 Spinal Muscular Atrophy Medicine Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4.1 The Market Share of United States Spinal Muscular Atrophy Medicine in Global, 2017 VS 2022 VS 2028
1.4.2 The Growth Rate of Spinal Muscular Atrophy Medicine Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.5 Spinal Muscular Atrophy Medicine Market Dynamics
1.5.1 Spinal Muscular Atrophy Medicine Industry Trends
1.5.2 Spinal Muscular Atrophy Medicine Market Drivers
1.5.3 Spinal Muscular Atrophy Medicine Market Challenges
1.5.4 Spinal Muscular Atrophy Medicine Market Restraints
1.6 Study Objectives
1.7 Years Considered
2 Market by Type
2.1 Spinal Muscular Atrophy Medicine Market Segment by Type
2.1.1 LMI-070
2.1.2 ND-602
2.1.3 NT-1654
2.1.4 Nusinersen
2.1.5 NXD-30001
2.1.6 Others
2.2 Global Spinal Muscular Atrophy Medicine Market Size by Type
2.2.1 Global Spinal Muscular Atrophy Medicine Sales in Value, by Type (2017, 2022 & 2028)
2.2.2 Global Spinal Muscular Atrophy Medicine Sales in Volume, by Type (2017, 2022 & 2028)
2.2.3 Global Spinal Muscular Atrophy Medicine Average Selling Price (ASP) by Type (2017, 2022 & 2028)
2.3 United States Spinal Muscular Atrophy Medicine Market Size by Type
2.3.1 United States Spinal Muscular Atrophy Medicine Sales in Value, by Type (2017, 2022 & 2028)
2.3.2 United States Spinal Muscular Atrophy Medicine Sales in Volume, by Type (2017, 2022 & 2028)
2.3.3 United States Spinal Muscular Atrophy Medicine Average Selling Price (ASP) by Type (2017, 2022 & 2028)
3 Market by Application
3.1 Spinal Muscular Atrophy Medicine Market Segment by Application
3.1.1 Hospital
3.1.2 Clinic
3.1.3 Others
3.2 Global Spinal Muscular Atrophy Medicine Market Size by Application
3.2.1 Global Spinal Muscular Atrophy Medicine Sales in Value, by Application (2017, 2022 & 2028)
3.2.2 Global Spinal Muscular Atrophy Medicine Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 Global Spinal Muscular Atrophy Medicine Average Selling Price (ASP) by Application (2017, 2022 & 2028)
3.3 United States Spinal Muscular Atrophy Medicine Market Size by Application
3.3.1 United States Spinal Muscular Atrophy Medicine Sales in Value, by Application (2017, 2022 & 2028)
3.3.2 United States Spinal Muscular Atrophy Medicine Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 United States Spinal Muscular Atrophy Medicine Average Selling Price (ASP) by Application (2017, 2022 & 2028)
4 Global Spinal Muscular Atrophy Medicine Competitor Landscape by Company
4.1 Global Spinal Muscular Atrophy Medicine Market Size by Company
4.1.1 Top Global Spinal Muscular Atrophy Medicine Manufacturers Ranked by Revenue (2021)
4.1.2 Global Spinal Muscular Atrophy Medicine Revenue by Manufacturer (2017-2022)
4.1.3 Global Spinal Muscular Atrophy Medicine Sales by Manufacturer (2017-2022)
4.1.4 Global Spinal Muscular Atrophy Medicine Price by Manufacturer (2017-2022)
4.2 Global Spinal Muscular Atrophy Medicine Concentration Ratio (CR)
4.2.1 Spinal Muscular Atrophy Medicine Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Spinal Muscular Atrophy Medicine in 2021
4.2.3 Global Spinal Muscular Atrophy Medicine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Spinal Muscular Atrophy Medicine Manufacturing Base Distribution, Product Type
4.3.1 Global Spinal Muscular Atrophy Medicine Manufacturers, Headquarters and Distribution of Producing Region
4.3.2 Manufacturers Spinal Muscular Atrophy Medicine Product Type
4.3.3 Date of International Manufacturers Enter into Spinal Muscular Atrophy Medicine Market
4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
4.5 United States Spinal Muscular Atrophy Medicine Market Size by Company
4.5.1 Top Spinal Muscular Atrophy Medicine Players in United States, Ranked by Revenue (2021)
4.5.2 United States Spinal Muscular Atrophy Medicine Revenue by Players (2020, 2021 & 2022)
4.5.3 United States Spinal Muscular Atrophy Medicine Sales by Players (2020, 2021 & 2022)
5 Global Spinal Muscular Atrophy Medicine Market Size by Region
5.1 Global Spinal Muscular Atrophy Medicine Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Spinal Muscular Atrophy Medicine Market Size in Volume by Region (2017-2028)
5.2.1 Global Spinal Muscular Atrophy Medicine Sales in Volume by Region: 2017-2022
5.2.2 Global Spinal Muscular Atrophy Medicine Sales in Volume Forecast by Region (2023-2028)
5.3 Global Spinal Muscular Atrophy Medicine Market Size in Value by Region (2017-2028)
5.3.1 Global Spinal Muscular Atrophy Medicine Sales in Value by Region: 2017-2022
5.3.2 Global Spinal Muscular Atrophy Medicine Sales in Value by Region: 2023-2028
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Spinal Muscular Atrophy Medicine Market Size YoY Growth 2017-2028
6.1.2 North America Spinal Muscular Atrophy Medicine Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Spinal Muscular Atrophy Medicine Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Spinal Muscular Atrophy Medicine Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Spinal Muscular Atrophy Medicine Market Size YoY Growth 2017-2028
6.3.2 Europe Spinal Muscular Atrophy Medicine Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Spinal Muscular Atrophy Medicine Market Size YoY Growth 2017-2028
6.4.2 Latin America Spinal Muscular Atrophy Medicine Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Spinal Muscular Atrophy Medicine Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Spinal Muscular Atrophy Medicine Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Astellas Pharma Inc.
7.1.1 Astellas Pharma Inc. Corporation Information
7.1.2 Astellas Pharma Inc. Description and Business Overview
7.1.3 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2017-2022)
7.1.4 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Products Offered
7.1.5 Astellas Pharma Inc. Recent Development
7.2 AveXis, Inc.
7.2.1 AveXis, Inc. Corporation Information
7.2.2 AveXis, Inc. Description and Business Overview
7.2.3 AveXis, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2017-2022)
7.2.4 AveXis, Inc. Spinal Muscular Atrophy Medicine Products Offered
7.2.5 AveXis, Inc. Recent Development
7.3 Bioblast Pharma Ltd.
7.3.1 Bioblast Pharma Ltd. Corporation Information
7.3.2 Bioblast Pharma Ltd. Description and Business Overview
7.3.3 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2017-2022)
7.3.4 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Products Offered
7.3.5 Bioblast Pharma Ltd. Recent Development
7.4 Cytokinetics, Inc. 24
7.4.1 Cytokinetics, Inc. 24 Corporation Information
7.4.2 Cytokinetics, Inc. 24 Description and Business Overview
7.4.3 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2017-2022)
7.4.4 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Products Offered
7.4.5 Cytokinetics, Inc. 24 Recent Development
7.5 F. Hoffmann-La Roche Ltd.
7.5.1 F. Hoffmann-La Roche Ltd. Corporation Information
7.5.2 F. Hoffmann-La Roche Ltd. Description and Business Overview
7.5.3 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2017-2022)
7.5.4 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Products Offered
7.5.5 F. Hoffmann-La Roche Ltd. Recent Development
7.6 Genethon
7.6.1 Genethon Corporation Information
7.6.2 Genethon Description and Business Overview
7.6.3 Genethon Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2017-2022)
7.6.4 Genethon Spinal Muscular Atrophy Medicine Products Offered
7.6.5 Genethon Recent Development
7.7 Genzyme Corporation
7.7.1 Genzyme Corporation Corporation Information
7.7.2 Genzyme Corporation Description and Business Overview
7.7.3 Genzyme Corporation Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2017-2022)
7.7.4 Genzyme Corporation Spinal Muscular Atrophy Medicine Products Offered
7.7.5 Genzyme Corporation Recent Development
7.8 GMP-Orphan SAS
7.8.1 GMP-Orphan SAS Corporation Information
7.8.2 GMP-Orphan SAS Description and Business Overview
7.8.3 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2017-2022)
7.8.4 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Products Offered
7.8.5 GMP-Orphan SAS Recent Development
7.9 Ionis Pharmaceuticals, Inc.
7.9.1 Ionis Pharmaceuticals, Inc. Corporation Information
7.9.2 Ionis Pharmaceuticals, Inc. Description and Business Overview
7.9.3 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2017-2022)
7.9.4 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Products Offered
7.9.5 Ionis Pharmaceuticals, Inc. Recent Development
7.10 Longevity Biotech, Inc
7.10.1 Longevity Biotech, Inc Corporation Information
7.10.2 Longevity Biotech, Inc Description and Business Overview
7.10.3 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2017-2022)
7.10.4 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Products Offered
7.10.5 Longevity Biotech, Inc Recent Development
7.11 Neurodyn Inc.
7.11.1 Neurodyn Inc. Corporation Information
7.11.2 Neurodyn Inc. Description and Business Overview
7.11.3 Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2017-2022)
7.11.4 Neurodyn Inc. Spinal Muscular Atrophy Medicine Products Offered
7.11.5 Neurodyn Inc. Recent Development
7.12 Neurotune AG
7.12.1 Neurotune AG Corporation Information
7.12.2 Neurotune AG Description and Business Overview
7.12.3 Neurotune AG Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2017-2022)
7.12.4 Neurotune AG Products Offered
7.12.5 Neurotune AG Recent Development
7.13 Novartis AG
7.13.1 Novartis AG Corporation Information
7.13.2 Novartis AG Description and Business Overview
7.13.3 Novartis AG Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2017-2022)
7.13.4 Novartis AG Products Offered
7.13.5 Novartis AG Recent Development
7.14 Sarepta Therapeutics, Inc.
7.14.1 Sarepta Therapeutics, Inc. Corporation Information
7.14.2 Sarepta Therapeutics, Inc. Description and Business Overview
7.14.3 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2017-2022)
7.14.4 Sarepta Therapeutics, Inc. Products Offered
7.14.5 Sarepta Therapeutics, Inc. Recent Development
7.15 Voyager Therapeutics, Inc.
7.15.1 Voyager Therapeutics, Inc. Corporation Information
7.15.2 Voyager Therapeutics, Inc. Description and Business Overview
7.15.3 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2017-2022)
7.15.4 Voyager Therapeutics, Inc. Products Offered
7.15.5 Voyager Therapeutics, Inc. Recent Development
7.16 Vybion, Inc.
7.16.1 Vybion, Inc. Corporation Information
7.16.2 Vybion, Inc. Description and Business Overview
7.16.3 Vybion, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2017-2022)
7.16.4 Vybion, Inc. Products Offered
7.16.5 Vybion, Inc. Recent Development
7.17 WAVE Life Sciences Ltd.
7.17.1 WAVE Life Sciences Ltd. Corporation Information
7.17.2 WAVE Life Sciences Ltd. Description and Business Overview
7.17.3 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2017-2022)
7.17.4 WAVE Life Sciences Ltd. Products Offered
7.17.5 WAVE Life Sciences Ltd. Recent Development
8 Industry Chain and Sales Channels Analysis
8.1 Spinal Muscular Atrophy Medicine Industry Chain Analysis
8.2 Spinal Muscular Atrophy Medicine Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 Spinal Muscular Atrophy Medicine Distributors
8.3 Spinal Muscular Atrophy Medicine Production Mode & Process
8.4 Spinal Muscular Atrophy Medicine Sales and Marketing
8.4.1 Spinal Muscular Atrophy Medicine Sales Channels
8.4.2 Spinal Muscular Atrophy Medicine Distributors
8.5 Spinal Muscular Atrophy Medicine Customers
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
Ask Our Expert

Leave This Empty:

*Required Information
List of Tables
Table 1. Spinal Muscular Atrophy Medicine CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
Table 2. Spinal Muscular Atrophy Medicine Market Trends
Table 3. Spinal Muscular Atrophy Medicine Market Drivers
Table 4. Spinal Muscular Atrophy Medicine Market Challenges
Table 5. Spinal Muscular Atrophy Medicine Market Restraints
Table 6. Global Spinal Muscular Atrophy Medicine Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 7. United States Spinal Muscular Atrophy Medicine Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 8. Global Spinal Muscular Atrophy Medicine Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 9. United States Spinal Muscular Atrophy Medicine Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 10. Top Spinal Muscular Atrophy Medicine Manufacturers in Global Market, Ranking by Revenue (2021)
Table 11. Global Spinal Muscular Atrophy Medicine Revenue by Manufacturer, (US$ Million), 2017-2022
Table 12. Global Spinal Muscular Atrophy Medicine Revenue Share by Manufacturer, 2017-2022
Table 13. Global Spinal Muscular Atrophy Medicine Sales by Manufacturer, (K Pcs), 2017-2022
Table 14. Global Spinal Muscular Atrophy Medicine Sales Share by Manufacturer, 2017-2022
Table 15. Global Spinal Muscular Atrophy Medicine Price by Manufacturer (2017-2022) & (USD/Pcs)
Table 16. Global Spinal Muscular Atrophy Medicine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global Spinal Muscular Atrophy Medicine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Spinal Muscular Atrophy Medicine as of 2021)
Table 18. Top Players of Spinal Muscular Atrophy Medicine in Global Market, Headquarters and Distribution of Producing Region
Table 19. Manufacturers Spinal Muscular Atrophy Medicine Product Type
Table 20. Date of International Manufacturers Enter into Spinal Muscular Atrophy Medicine Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Top Spinal Muscular Atrophy Medicine Players in United States Market, Ranking by Revenue (2021)
Table 23. United States Spinal Muscular Atrophy Medicine Revenue by Players, (US$ Million), 2020, 2021 & 2022
Table 24. United States Spinal Muscular Atrophy Medicine Revenue Share by Players, 2020, 2021 & 2022
Table 25. United States Spinal Muscular Atrophy Medicine Sales by Players, (K Pcs), 2020, 2021 & 2022
Table 26. United States Spinal Muscular Atrophy Medicine Sales Share by Players, 2020, 2021 & 2022
Table 27. Global Spinal Muscular Atrophy Medicine Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
Table 28. Global Spinal Muscular Atrophy Medicine Sales in Volume by Region (2017-2022) & (K Pcs)
Table 29. Global Spinal Muscular Atrophy Medicine Sales in Volume Forecast by Region (2023-2028) & (K Pcs)
Table 30. Global Spinal Muscular Atrophy Medicine Sales in Value by Region (2017-2022) & (US$ Million)
Table 31. Global Spinal Muscular Atrophy Medicine Sales in Value Forecast by Region (2023-2028) & (US$ Million)
Table 32. North America Spinal Muscular Atrophy Medicine Sales in Volume by Country (2017-2028) & (K Pcs)
Table 33. North America Spinal Muscular Atrophy Medicine Sales in Value by Country (2017-2028) & (US$ Million)
Table 34. Asia Pacific Spinal Muscular Atrophy Medicine Sales in Volume by Region (2017-2028) & (K Pcs)
Table 35. Asia Pacific Spinal Muscular Atrophy Medicine Sales in Value by Region (2017-2028) & (US$ Million)
Table 36. Europe Spinal Muscular Atrophy Medicine Sales in Volume by Country (2017-2028) & (K Pcs)
Table 37. Europe Spinal Muscular Atrophy Medicine Sales in Value by Country (2017-2028) & (US$ Million)
Table 38. Latin America Spinal Muscular Atrophy Medicine Sales in Volume by Country (2017-2028) & (K Pcs)
Table 39. Latin Americaa Spinal Muscular Atrophy Medicine Sales in Value by Country (2017-2028) & (US$ Million)
Table 40. Middle East and Africa Spinal Muscular Atrophy Medicine Sales in Volume by Country (2017-2028) & (K Pcs)
Table 41. Middle East and Africa Spinal Muscular Atrophy Medicine Sales in Value by Country (2017-2028) & (US$ Million)
Table 42. Astellas Pharma Inc. Corporation Information
Table 43. Astellas Pharma Inc. Description and Business Overview
Table 44. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 45. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product
Table 46. Astellas Pharma Inc. Recent Development
Table 47. AveXis, Inc. Corporation Information
Table 48. AveXis, Inc. Description and Business Overview
Table 49. AveXis, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 50. AveXis, Inc. Product
Table 51. AveXis, Inc. Recent Development
Table 52. Bioblast Pharma Ltd. Corporation Information
Table 53. Bioblast Pharma Ltd. Description and Business Overview
Table 54. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 55. Bioblast Pharma Ltd. Product
Table 56. Bioblast Pharma Ltd. Recent Development
Table 57. Cytokinetics, Inc. 24 Corporation Information
Table 58. Cytokinetics, Inc. 24 Description and Business Overview
Table 59. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 60. Cytokinetics, Inc. 24 Product
Table 61. Cytokinetics, Inc. 24 Recent Development
Table 62. F. Hoffmann-La Roche Ltd. Corporation Information
Table 63. F. Hoffmann-La Roche Ltd. Description and Business Overview
Table 64. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 65. F. Hoffmann-La Roche Ltd. Product
Table 66. F. Hoffmann-La Roche Ltd. Recent Development
Table 67. Genethon Corporation Information
Table 68. Genethon Description and Business Overview
Table 69. Genethon Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 70. Genethon Product
Table 71. Genethon Recent Development
Table 72. Genzyme Corporation Corporation Information
Table 73. Genzyme Corporation Description and Business Overview
Table 74. Genzyme Corporation Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 75. Genzyme Corporation Product
Table 76. Genzyme Corporation Recent Development
Table 77. GMP-Orphan SAS Corporation Information
Table 78. GMP-Orphan SAS Description and Business Overview
Table 79. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 80. GMP-Orphan SAS Product
Table 81. GMP-Orphan SAS Recent Development
Table 82. Ionis Pharmaceuticals, Inc. Corporation Information
Table 83. Ionis Pharmaceuticals, Inc. Description and Business Overview
Table 84. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 85. Ionis Pharmaceuticals, Inc. Product
Table 86. Ionis Pharmaceuticals, Inc. Recent Development
Table 87. Longevity Biotech, Inc Corporation Information
Table 88. Longevity Biotech, Inc Description and Business Overview
Table 89. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 90. Longevity Biotech, Inc Product
Table 91. Longevity Biotech, Inc Recent Development
Table 92. Neurodyn Inc. Corporation Information
Table 93. Neurodyn Inc. Description and Business Overview
Table 94. Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 95. Neurodyn Inc. Product
Table 96. Neurodyn Inc. Recent Development
Table 97. Neurotune AG Corporation Information
Table 98. Neurotune AG Description and Business Overview
Table 99. Neurotune AG Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 100. Neurotune AG Product
Table 101. Neurotune AG Recent Development
Table 102. Novartis AG Corporation Information
Table 103. Novartis AG Description and Business Overview
Table 104. Novartis AG Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 105. Novartis AG Product
Table 106. Novartis AG Recent Development
Table 107. Sarepta Therapeutics, Inc. Corporation Information
Table 108. Sarepta Therapeutics, Inc. Description and Business Overview
Table 109. Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 110. Sarepta Therapeutics, Inc. Product
Table 111. Sarepta Therapeutics, Inc. Recent Development
Table 112. Voyager Therapeutics, Inc. Corporation Information
Table 113. Voyager Therapeutics, Inc. Description and Business Overview
Table 114. Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 115. Voyager Therapeutics, Inc. Product
Table 116. Voyager Therapeutics, Inc. Recent Development
Table 117. Vybion, Inc. Corporation Information
Table 118. Vybion, Inc. Description and Business Overview
Table 119. Vybion, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 120. Vybion, Inc. Product
Table 121. Vybion, Inc. Recent Development
Table 122. WAVE Life Sciences Ltd. Corporation Information
Table 123. WAVE Life Sciences Ltd. Description and Business Overview
Table 124. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 125. WAVE Life Sciences Ltd. Product
Table 126. WAVE Life Sciences Ltd. Recent Development
Table 127. Key Raw Materials Lists
Table 128. Raw Materials Key Suppliers Lists
Table 129. Spinal Muscular Atrophy Medicine Customers List
Table 130. Spinal Muscular Atrophy Medicine Distributors List
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
List of Figures
Figure 1. Spinal Muscular Atrophy Medicine Product Picture
Figure 2. Global Spinal Muscular Atrophy Medicine Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 3. Global Spinal Muscular Atrophy Medicine Market Size 2017-2028 (US$ Million)
Figure 4. Global Spinal Muscular Atrophy Medicine Sales 2017-2028 (K Pcs)
Figure 5. United States Spinal Muscular Atrophy Medicine Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 6. United States Spinal Muscular Atrophy Medicine Market Size 2017-2028 (US$ Million)
Figure 7. United States Spinal Muscular Atrophy Medicine Sales 2017-2028 (K Pcs)
Figure 8. United States Spinal Muscular Atrophy Medicine Market Share in Global, in Value (US$ Million) 2017-2028
Figure 9. United States Spinal Muscular Atrophy Medicine Market Share in Global, in Volume (K Pcs) 2017-2028
Figure 10. Spinal Muscular Atrophy Medicine Report Years Considered
Figure 11. Product Picture of LMI-070
Figure 12. Product Picture of ND-602
Figure 13. Product Picture of NT-1654
Figure 14. Product Picture of Nusinersen
Figure 15. Product Picture of NXD-30001
Figure 16. Product Picture of Others
Figure 17. Global Spinal Muscular Atrophy Medicine Market Share by Type in 2022 & 2028
Figure 18. Global Spinal Muscular Atrophy Medicine Sales in Value by Type (2017-2028) & (US$ Million)
Figure 19. Global Spinal Muscular Atrophy Medicine Sales Market Share in Value by Type (2017-2028)
Figure 20. Global Spinal Muscular Atrophy Medicine Sales by Type (2017-2028) & (K Pcs)
Figure 21. Global Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Type (2017-2028)
Figure 22. Global Spinal Muscular Atrophy Medicine Price by Type (2017-2028) & (USD/Pcs)
Figure 23. United States Spinal Muscular Atrophy Medicine Market Share by Type in 2022 & 2028
Figure 24. United States Spinal Muscular Atrophy Medicine Sales in Value by Type (2017-2028) & (US$ Million)
Figure 25. United States Spinal Muscular Atrophy Medicine Sales Market Share in Value by Type (2017-2028)
Figure 26. United States Spinal Muscular Atrophy Medicine Sales by Type (2017-2028) & (K Pcs)
Figure 27. United States Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Type (2017-2028)
Figure 28. United States Spinal Muscular Atrophy Medicine Price by Type (2017-2028) & (USD/Pcs)
Figure 29. Product Picture of Hospital
Figure 30. Product Picture of Clinic
Figure 31. Product Picture of Others
Figure 32. Global Spinal Muscular Atrophy Medicine Market Share by Application in 2022 & 2028
Figure 33. Global Spinal Muscular Atrophy Medicine Sales in Value by Application (2017-2028) & (US$ Million)
Figure 34. Global Spinal Muscular Atrophy Medicine Sales Market Share in Value by Application (2017-2028)
Figure 35. Global Spinal Muscular Atrophy Medicine Sales by Application (2017-2028) & (K Pcs)
Figure 36. Global Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Application (2017-2028)
Figure 37. Global Spinal Muscular Atrophy Medicine Price by Application (2017-2028) & (USD/Pcs)
Figure 38. United States Spinal Muscular Atrophy Medicine Market Share by Application in 2022 & 2028
Figure 39. United States Spinal Muscular Atrophy Medicine Sales in Value by Application (2017-2028) & (US$ Million)
Figure 40. United States Spinal Muscular Atrophy Medicine Sales Market Share in Value by Application (2017-2028)
Figure 41. United States Spinal Muscular Atrophy Medicine Sales by Application (2017-2028) & (K Pcs)
Figure 42. United States Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Application (2017-2028)
Figure 43. United States Spinal Muscular Atrophy Medicine Price by Application (2017-2028) & (USD/Pcs)
Figure 44. North America Spinal Muscular Atrophy Medicine Sales in Volume Growth Rate 2017-2028 (K Pcs)
Figure 45. North America Spinal Muscular Atrophy Medicine Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 46. U.S. Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 47. Canada Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 48. Europe Spinal Muscular Atrophy Medicine Sales in Volume Growth Rate 2017-2028 (K Pcs)
Figure 49. Europe Spinal Muscular Atrophy Medicine Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 50. Germany Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 51. France Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 52. U.K. Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 53. Italy Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 54. Russia Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 55. Asia-Pacific Spinal Muscular Atrophy Medicine Sales in Volume Growth Rate 2017-2028 (K Pcs)
Figure 56. Asia-Pacific Spinal Muscular Atrophy Medicine Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 57. China Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 58. Japan Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 59. South Korea Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 60. India Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 61. Australia Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 62. Taiwan Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 63. Indonesia Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 64. Thailand Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 65. Malaysia Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 66. Philippines Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 67. Latin America Spinal Muscular Atrophy Medicine Sales in Volume Growth Rate 2017-2028 (K Pcs)
Figure 68. Latin America Spinal Muscular Atrophy Medicine Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 69. Mexico Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 70. Brazil Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 71. Argentina Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 72. Middle East & Africa Spinal Muscular Atrophy Medicine Sales in Volume Growth Rate 2017-2028 (K Pcs)
Figure 73. Middle East & Africa Spinal Muscular Atrophy Medicine Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 74. Turkey Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 75. Saudi Arabia Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 76. U.A.E Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 77. Spinal Muscular Atrophy Medicine Value Chain
Figure 78. Spinal Muscular Atrophy Medicine Production Process
Figure 79. Channels of Distribution
Figure 80. Distributors Profiles
Figure 81. Bottom-up and Top-down Approaches for This Report
Figure 82. Data Triangulation
Figure 83. Key Executives Interviewed

Buy Full Report

Select Licence type with your requirement and needs

SECURITY ASSUREDpayment image

analyst icon
Still not found what you want?

Speak to our Custom Research Team and get the Custom Research in a budget

Custom Research


Frequently Asked Questions ?

  • A license granted to one user.

    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License

    A license granted to multiple users.

  • Site License

    A license granted to a single business site/establishment.

  • Corporate License, Global License

    A license granted to all employees within organisation access to the product.

  • Upto Working 24 to 48 hrs

  • Upto 72 hrs max - Weekends and Public Holidays

  • Online Payments with PayPal and CCavenue

  • Wire Transfer/Bank Transfer

  • Email

  • Hard Copy

WHY CHOOSE US

  • Proactive We manage our resources 24/7 to identify issues and address them before they become problems
  • Quality & Reliability We are committed to providing reliable and highly accurate data with an excellent quality control system
  • Global Outreach 6 Major regions and 40+ countries level analysis accomplished
  • Competitive Pricing Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery

SAMPLE REPORT INCLUDES
  • Industry Market SizeIndustry Market Size
  • SWOT AnalysisSWOT Analysis
  • Industry Major PlayersIndustry Major Players
  • Revenue ForecastsRevenue Forecasts
  • Historical and Forecast GrowthHistorical and Forecast Growth
  • Profitability AnalysisProfitability Analysis
SOME OF OUR CLIENTS
WHAT SET US APART?
  • quilty

    Quality Assurance

    Focus on Data Accuracy & Reliability
  • quilty

    Trusted by the Best

    75+ Clients in Fortune 500
  • quilty

    Privacy and Security

    All your transactions are secured end-to-end, ensuring a satisfactory purchase
  • quilty

    Competitive Pricing

    Ensure the best and affordable pricing
OUR HAPPY CUSTOMER Some of our customer review
Stay Updated About Spinal Muscular Atrophy Medicine Market

Leave This Empty: